Nada Hamad is a Hematologist-Oncologist based at 160 Oxford St, Darlinghurst, NSW 2010. She looks after people with blood and bone marrow conditions, along with some cancers that affect the blood and lymph system.
Her work covers a wide range of issues. This includes common blood cancer types like leukaemias and lymphomas, and also conditions that affect the blood counts, such as anaemia and low platelets. At times she also helps manage long-term complications that can happen after bone marrow or stem cell treatment, including graft versus host disease.
Many appointments focus on making sense of symptoms and test results. That might be ongoing tiredness, fevers, swollen glands, unusual bruising, or blood results that don’t look right. Over time, the plan is often built around what the results show, the person’s overall health, and how the condition is behaving.
Nada’s approach is practical and patient-centred. She works with other specialists to coordinate care, especially when treatment needs to be planned in steps. In many cases, that means bringing together haematology, oncology, nursing support, and pharmacy, so nothing important gets missed.
When treatment is needed, the focus is on options and timing. This can include chemotherapy, supportive care, and managing side effects. For people needing more intensive care, she helps explain what bone marrow transplant and related care can involve, and what follow-up looks like afterwards.
She also spends time on quality-of-life issues. For example, some patients need help with infection risks, breathing issues, or other problems that come up during treatment. Conditions like pneumonia can be part of the bigger picture, and her role is to help guide safe care through those rough patches.
Education details and formal training information aren’t listed here, but her work is built on solid clinical practice in blood cancer and transplant-related care. She keeps up with new knowledge in the field, including research that may lead to better treatments.
For some people, clinical trials can be worth considering. If it fits a patient’s situation, she can discuss whether a clinical trial might be an option, alongside standard treatment. That way, decisions are made with clear information and a steady plan.
